The DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
Interleukin-2 and Regulatory T Cells in Graft-versus-Host Disease
Open accessAbstract
BACKGROUND: Dysfunction of regulatory T (Treg) cells has been detected in diverse inflammatory disorders, including chronic graft-versus-host disease (GVHD). Interleukin-2 is critical for Treg cell growth, survival, and activity. We hypothesized that low-dose interleukin-2 could preferentially enhance Treg cells in vivo and suppress clinical manifestations of chronic GVHD. METHODS: In this observational cohort study, patients with chronic GVHD that was refractory to glucocorticoid therapy received daily low-dose subcutaneous interleukin-2 (0.3×10(6), 1×10(6), or 3×10(6) IU per square meter of body-surface area) for 8 weeks. The end points were safety and clinical and immunologic response. After a 4-week hiatus, patients with a response could receive interleukin-2 for an extended period. RESULTS: A total of 29 patients were enrolled. None had progression of chronic GVHD or relapse of a hematologic cancer. The maximum tolerated dose of interleukin-2 was 1×10(6) IU per square meter. The highest dose level induced unacceptable constitutional symptoms. Of the 23 patients who could be evaluated for response, 12 had major responses involving multiple sites. The numbers of CD4+ Treg cells were preferentially increased in all patients, with a peak median value, at 4 weeks, that was more than eight times the baseline value (P<0.001), without affecting CD4+ conventional T (Tcon) cells. The Treg:Tcon ratio increased to a median of more than five times the baseline value (P<0.001). The Treg cell count and Treg:Tcon ratio remained elevated at 8 weeks (P<0.001 for both comparisons with baseline values), then declined when the patients were not receiving interleukin-2. The increased numbers of Treg cells expressed the transcription factor forkhead box P3 (FOXP3) and could inhibit autologous Tcon cells. Immunologic and clinical responses were sustained in patients who received interleukin-2 for an extended period, permitting the glucocorticoid dose to be tapered by a mean of 60% (range, 25 to 100). CONCLUSIONS: Daily low-dose interleukin-2 was safely administered in patients with active chronic GVHD that was refractory to glucocorticoid therapy. Administration was associated with preferential, sustained Treg cell expansion in vivo and amelioration of the manifestations of chronic GVHD in a substantial proportion of patients. (Funded by a Dana-Farber Dunkin' Donuts Rising Star award and others; ClinicalTrials.gov number, NCT00529035.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Jagasia, M. H., Greinix, H. T., Arora, M., Williams, K. M., Wolff, D., Cowen, E. W., Palmer, J., Weisdorf, D., Treister, N. S., Cheng, G.-S., et al. (2015) · Biology of Blood and Marrow Transplantation · doi:10.1016/j.bbmt.2014.12.001 · Cited by 5,459
Self-citationFilipovich, A. H., Weisdorf, D., Pavletic, S., Socie, G., Wingard, J. R., Lee, S. J., Martin, P., Chien, J., Przepiorka, D., Couriel, D., et al. (2005) · Biology of Blood and Marrow Transplantation · doi:10.1016/j.bbmt.2005.09.004 · Cited by 3,556
Thornton, A. M., & Shevach, E. M. (1998) · The Journal of Experimental Medicine · doi:10.1084/jem.188.2.287 · Cited by 2,639
CD127 expression inversely correlates with FoxP3 and suppressive function of human CD4+ T reg cells
Liu, W., Putnam, A. L., Xu-yu, Z., Szot, G. L., Lee, M. R., Zhu, S., Gottlieb, P. A., Kapranov, P., Gingeras, T. R., de St. Groth, B. F., et al. (2006) · The Journal of Experimental Medicine · doi:10.1084/jem.20060772 · Cited by 2,606
Seddiki, N., Santner-Nanan, B., Martinson, J., Zaunders, J., Sasson, S., Landay, A., Solomon, M., Selby, W., Alexander, S. I., Nanan, R., et al. (2006) · The Journal of Experimental Medicine · doi:10.1084/jem.20060468 · Cited by 1,512
Edinger, M., Hoffmann, P., Ermann, J., Drago, K., Fathman, C. G., Strober, S., & Negrin, R. S. (2003) · Nature Medicine · doi:10.1038/nm915 · Cited by 1,288
In Vitro–expanded Antigen-specific Regulatory T Cells Suppress Autoimmune Diabetes
Tang, Q., Henriksen, K. J., Bi, M., Finger, E. B., Szot, G., Ye, J., Masteller, E. L., McDevitt, H., Bonyhadi, M., & Bluestone, J. A. (2004) · The Journal of Experimental Medicine · doi:10.1084/jem.20040139 · Cited by 1,221
Hoffmann, P., Ermann, J., Edinger, M., Fathman, C. G., & Strober, S. (2002) · The Journal of Experimental Medicine · doi:10.1084/jem.20020399 · Cited by 1,098
Tregs prevent GVHD and promote immune reconstitution in HLA-haploidentical transplantation
Di Ianni, M., Falzetti, F., Carotti, A., Terenzi, A., Castellino, F., Bonifacio, E., Del Papa, B., Zei, T., Ostini, R. I., Cecchini, D., et al. (2011) · Blood · doi:10.1182/blood-2010-10-311894 · Cited by 1,064
Brunstein, C. G., Miller, J. S., Cao, Q., McKenna, D. H., Hippen, K. L., Curtsinger, J., DeFor, T., Levine, B. L., June, C. H., Rubinstein, P., et al. (2011) · Blood · doi:10.1182/blood-2010-07-293795 · Cited by 1,045
Taylor, P. A., Lees, C. J., & Blazar, B. R. (2002) · Blood · doi:10.1182/blood.v99.10.3493 · Cited by 1,041
Cutting Edge: Cure of Colitis by CD4+CD25+ Regulatory T Cells
Mottet, C., Uhlig, H. H., & Powrie, F. (2003) · The Journal of Immunology · doi:10.4049/jimmunol.170.8.3939 · Cited by 927
Tolerance, not immunity, crucially depends on IL-2
Malek, T. R., & Bayer, A. L. (2004) · Nature Reviews Immunology · doi:10.1038/nri1435 · Cited by 820
Mechanisms of impaired regulation by CD4+CD25+FOXP3+ regulatory T cells in human autoimmune diseases
Buckner, J. H. (2010) · Nature Reviews Immunology · doi:10.1038/nri2889 · Cited by 789
Zorn, E., Nelson, E. A., Mohseni, M., Porcheray, F., Kim, H., Litsa, D., Bellucci, R., Raderschall, E., Canning, C., Soiffer, R. J., et al. (2006) · Blood · doi:10.1182/blood-2006-02-004747 · Cited by 740
Self-citationCD4+CD25+ TR Cells Suppress Innate Immune Pathology Through Cytokine-dependent Mechanisms
Maloy, K. J., Salaun, L., Cahill, R., Dougan, G., Saunders, N. J., & Powrie, F. (2003) · The Journal of Experimental Medicine · doi:10.1084/jem.20021345 · Cited by 739
CD4+CD25+ Immunoregulatory T Cells
Cohen, J. L., Trenado, A., Vasey, D., Klatzmann, D., & Salomon, B. L. (2002) · The Journal of Experimental Medicine · doi:10.1084/jem.20020090 · Cited by 687
Pavletic, S. Z., Martin, P., Lee, S. J., Mitchell, S., Jacobsohn, D., Cowen, E. W., Turner, M. L., Akpek, G., Gilman, A., McDonald, G., et al. (2006) · Biology of Blood and Marrow Transplantation · doi:10.1016/j.bbmt.2006.01.008 · Cited by 563
IL-2, Regulatory T Cells, and Tolerance
Nelson, B. H. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.172.7.3983 · Cited by 556
Regulatory T-cell immunotherapy for tolerance to self antigens and alloantigens in humans
Roncarolo, M.-G., & Battaglia, M. (2007) · Nature Reviews Immunology · doi:10.1038/nri2138 · Cited by 515
Inhibition of CD4+CD25+ regulatory T-cell function by calcineurin-dependent interleukin-2 production
Zeiser, R., Nguyen, V. H., Beilhack, A., Buess, M., Schulz, S., Baker, J., Contag, C. H., & Negrin, R. S. (2006) · Blood · doi:10.1182/blood-2006-01-0329 · Cited by 504
Zorn, E., Kim, H. T., Lee, S. J., Floyd, B. H., Litsa, D., Arumugarajah, S., Bellucci, R., Alyea, E. P., Antin, J. H., Soiffer, R. J., et al. (2005) · Blood · doi:10.1182/blood-2005-03-1257 · Cited by 467
Self-citationPiccirillo, C. (2004) · Seminars in Immunology · doi:10.1016/j.smim.2003.12.003 · Cited by 392
Pidala, J., Kurland, B., Chai, X., Majhail, N., Weisdorf, D. J., Pavletic, S., Cutler, C., Jacobsohn, D., Palmer, J., Arai, S., et al. (2011) · Blood · doi:10.1182/blood-2010-11-319509 · Cited by 389
Self-citationInterleukin-2 Therapy in Patients with HIV Infection
(2009) · New England Journal of Medicine · doi:10.1056/nejmoa0903175 · Cited by 381
Tarbell, K. V., Petit, L., Zuo, X., Toy, P., Luo, X., Mqadmi, A., Yang, H., Suthanthiran, M., Mojsov, S., & Steinman, R. M. (2007) · The Journal of Experimental Medicine · doi:10.1084/jem.20061631 · Cited by 342
CD40 Ligation Releases Immature Dendritic Cells from the Control of Regulatory CD4+CD25+ T Cells
Serra, P., Amrani, A., Yamanouchi, J., Han, B., Thiessen, S., Utsugi, T., Verdaguer, J., & Santamaria, P. (2003) · Immunity · doi:10.1016/s1074-7613(03)00327-3 · Cited by 291
Matsuoka, K.-I., Kim, H. T., McDonough, S., Bascug, G., Warshauer, B., Koreth, J., Cutler, C., Ho, V. T., Alyea, E. P., Antin, J. H., et al. (2010) · Journal of Clinical Investigation · doi:10.1172/jci41072 · Cited by 243
Self-citationImatinib for refractory chronic graft-versus-host disease with fibrotic features
Olivieri, A., Locatelli, F., Zecca, M., Sanna, A., Cimminiello, M., Raimondi, R., Gini, G., Mordini, N., Balduzzi, A., Leoni, P., et al. (2009) · Blood · doi:10.1182/blood-2009-02-204156 · Cited by 231
Human CD4+ CD25+ regulatory T cells suppress NKT cell functions.
Azuma, T., Takahashi, T., Kunisato, A., Kitamura, T., & Hirai, H. (2003) · PubMed · Cited by 224
Development and function of CD25+CD4+ regulatory T cells
Fehérvari, Z., & Sakaguchi, S. (2004) · Current Opinion in Immunology · doi:10.1016/j.coi.2004.01.004 · Cited by 216
Soiffer, R., Murray, C., Cochran, K., Cameron, C., Wang, E., Schow, P., Daley, J., & Ritz, J. (1992) · Blood · doi:10.1182/blood.v79.2.517.517 · Cited by 197
Self-citationKahl, C., Storer, B. E., Sandmaier, B. M., Mielcarek, M., Maris, M. B., Blume, K. G., Niederwieser, D., Chauncey, T. R., Forman, S. J., Agura, E., et al. (2007) · Blood · doi:10.1182/blood-2007-03-078592 · Cited by 163
Janssens, W., Carlier, V. A., Wu, B., VanderElst, L., Jacquemin, M. G., & Saint-Remy, J.-M. (2003) · The Journal of Immunology · doi:10.4049/jimmunol.171.9.4604 · Cited by 146
Pérez‐Simón, J. A., Encinas, C., Silva, F., Arcos, M. J., Díez‐Campelo, M., Sanchez-Guijo, F. M., Colado, E., Martín, J., Vázquez, L., del Cañizo, C., et al. (2008) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2008.07.015 · Cited by 88
Current and future approaches for control of graft-versus-host disease
Koreth, J., & Antin, J. H. (2008) · Expert Review of Hematology · doi:10.1586/17474086.1.1.111 · Cited by 40
Self-citationRegulatory T Cells: Customizing for the Clinic
Wang, X., Lu, L., & Jiang, S. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3001819 · Cited by 35
Ladenstein, R. L., Pötschger, U., Siabalis, D., Garaventa, A., Bergeron, C., Lewis, I. J., Stein, J., Kohler, J., Shaw, P. J., Holter, W., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.5465 · Cited by 32
Tsuchihashi (2000) · doi:10.1002/1521-4141(200006)30:6
Cited by
The role of interleukin-2 during homeostasis and activation of the immune system
Boyman, O., & Sprent, J. (2012) · Nature Reviews Immunology · doi:10.1038/nri3156 · Cited by 1,657
Interleukin-2 at the Crossroads of Effector Responses, Tolerance, and Immunotherapy
Liao, W., Lin, J.-X., & Leonard, W. J. (2013) · Immunity · doi:10.1016/j.immuni.2013.01.004 · Cited by 1,075
Regulatory T-Cell Responses to Low-Dose Interleukin-2 in HCV-Induced Vasculitis
Saadoun, D., Rosenzwajg, M., Joly, F., Six, A., Carrat, F., Thibault, V., Sene, D., Cacoub, P., & Klatzmann, D. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1105143 · Cited by 762
Pathophysiology of Chronic Graft-versus-Host Disease and Therapeutic Targets
Zeiser, R., & Blazar, B. R. (2017) · New England Journal of Medicine · doi:10.1056/nejmra1703472 · Cited by 748
Treg cell-based therapies: challenges and perspectives
Raffin, C., Vo, L. T., & Bluestone, J. A. (2020) · Nature Reviews Immunology · doi:10.1038/s41577-019-0232-6 · Cited by 720
Metadata
- Authors
- Koreth, J., Matsuoka, K.-I., Kim, H. T., McDonough, S. M., Bindra, B., Alyea, E. P., Armand, P., Cutler, C., Ho, V. T., Treister, N. S., Bienfang, D. C., Prasad, S., Tzachanis, D., Joyce, R. M., Avigan, D. E., Antin, J. H., Ritz, J., & Soiffer, R. J.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2011-12
- Volume
- 365
- Issue
- 22
- Pages
- 2055-2066
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2086030126
- Cited by
- 1,119
- References
- 39
- FWCI
- 46.22
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.